Related Experiment Video
Updated: Apr 13, 2026
09:38
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
14.6K
[Haemostatic aspects in clinical oncology]
1Priv.-Doz. Dr. med. Florian Langer, II. Medizinische Klinik und Poliklinik, Hubertus-Wald-Tumorzentrum - Universitäres Cancer Center Hamburg (UCCH), Universitätsklinikum Eppendorf, Martinistr. 52, 20246 Hamburg, Tel. 040/74 105-24 53, -06 64, Fax -51 93,
Hamostaseologie
|May 7, 2015
Summary
Cancer patients often experience blood clots (thrombosis), impacting tumor growth and spread. While low-molecular-weight heparin (LMWH) treats existing clots, its role in cancer therapy requires further clinical validation.
Area of Science:
- Oncology and Hematology
- Molecular Biology
- Cancer Pathophysiology
Context:
- The association between cancer and thrombosis, known as Trousseau's syndrome, has been recognized since 1865.
- Coagulation and fibrinolysis are integral to both Trousseau's syndrome and the progression of solid tumors.
- Tissue factor plays a crucial role in primary tumor development and metastatic spread.
Purpose:
- To review the role of hemostatic perturbations in cancer progression.
- To discuss the current management of venous thromboembolism (VTE) in cancer patients.
- To explore the potential therapeutic role of low-molecular-weight heparin (LMWH) in cancer treatment.
Summary:
- Cancer-associated thrombosis involves complex hemostatic alterations, influenced by genetic events in tumorigenesis.
- Standard treatment for established VTE in cancer patients involves long-term low-molecular-weight heparin (LMWH).
- Pharmacological VTE prophylaxis and managing complex coagulopathies in ambulatory cancer patients present ongoing challenges, requiring individualized, risk-adapted approaches.
Impact:
- Understanding the interplay between cancer and coagulation is vital for improving patient outcomes.
- Further rigorous clinical trials are needed to confirm the potential benefits of LMWH in cancer therapy.
- This research highlights the need for personalized strategies in managing cancer-related hemostatic disorders.
Related Concept Videos
01:30Venous Thrombosis IV: Nursing Management
392
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
392
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
01:05Introduction to Hemostasis
17.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
17.9K
01:24Disorders of Hemostasis
2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
15.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.7K
01:29Venous Thrombosis III: Interprofessional Care
471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471